Avanos Strategy and Business Model

Executive Overview

Avanos is a focused medical-device company that competes in niches where clinician training, repeat use, and protocol adoption matter more than sheer product breadth. Headquartered in Alpharetta, Georgia, the company traces its current form to the 2014 spin-off of Kimberly-Clark’s health care business as Halyard Health and the 2018 rebranding to Avanos after divesting the surgical and infection-prevention business. Today Avanos concentrates on pain management, recovery, and digestive health. Its portfolio includes ON-Q surgical pain pumps, COOLIEF radiofrequency products, Game Ready recovery systems, and digestive-health brands such as MIC-KEY, CORTRAK, and NeoMed. Strategically, Avanos has been reshaping itself toward faster-growing, better-margin pain adjacencies while protecting its recurring enteral-feeding installed base. That matters because much of the business is driven by disposable or procedure-linked product use, while selected capital products can create recurring pull-through. The company sells mainly to hospitals, ambulatory surgery centers, pain specialists, orthopedic providers, and alternate-site care customers, with the United States as its largest market and distributors extending its reach internationally. In FY2024, Avanos reported #N/A of revenue.

Avanos at a Glance

Logo
Common name	Avanos
Full legal name	Avanos Medical, Inc.
Headquarters	Alpharetta, Georgia, United States
Ownership	Public company; no controlling shareholder publicly identified
Ticker	AVNS
Exchange	NYSE - New York Stock Exchange
Market Cap	$1.17B
Revenue (FY2024)	#N/A
Founding / major historical milestones	2014 spin-off from Kimberly-Clark as Halyard Health; 2018 rebranded as Avanos after sale of the Surgical & Infection Prevention business; later expanded through acquisitions including NeoMed, Game Ready, Diros Technology, and OrthogenRx
Industry or industries	Medical devices; pain management; recovery therapy; digestive health / enteral feeding
Key products or services	ON-Q, COOLIEF, Game Ready, MIC-KEY, CORTRAK, NeoMed, and related consumables and procedure products
Geographic footprint	U.S.-led commercial base with international sales through direct teams and distributors
Business segments as officially reported	One reportable segment; management discusses the business primarily through Pain Management and Recovery and Digestive Health product franchises
Company website	https://www.avanos.com/

1. What Is the Strategy of Avanos?

Based on Avanos’s FY2024 public filings, investor materials, and recent portfolio actions, the company’s strategy is to compete in focused medical-device categories where it can pair branded clinical products with repeat consumable demand and specialized selling. In Playing to Win terms, Avanos is not trying to be a broad hospital-supplies company; it is narrowing around pain management, recovery, and digestive health, then using targeted innovation and tuck-in acquisitions to improve its growth and margin profile.

1. 1a. What is the winning aspiration of Avanos?

   Avanos’s winning aspiration appears to be improving patient quality of life in pain management and digestive health while building a more durable, higher-margin medtech portfolio. In practical terms, “winning” means being a clinically relevant specialist rather than a commodity supplier: helping providers reduce opioid use in surgical and chronic pain pathways, improving recovery after orthopedic procedures, and supporting enteral feeding in acute, alternate-site, and home settings. Public communications also suggest a financial aspiration to return to sustainable profitable growth, expand margins through mix and productivity, and deploy capital into adjacencies that fit the company’s chosen call points.

2. 1b. Where does Avanos play?

   Avanos plays in selected medtech niches rather than across the full hospital products landscape. Its core arenas are pain management and recovery on one side and digestive health on the other. Within those, it focuses on operating rooms, ambulatory surgery centers, interventional pain clinics, orthopedic and sports-medicine settings, neonatal and pediatric feeding environments, and home or alternate-site care where enteral feeding products are used repeatedly. Geographically, the company is anchored in the United States and extends internationally through a mix of direct commercial activity and distributors. This is a relatively narrow “where to play” choice, but that narrowness is strategic: it avoids trying to out-scale diversified giants across all med-surg categories.

3. 1c. How does Avanos plan to win?

   Avanos appears to plan to win through clinical specialization, branded procedure products, and portfolio adjacency. In pain, that means offering non-opioid or opioid-sparing solutions, radiofrequency pain technologies, and recovery products that fit orthopedic and surgical care pathways. In digestive health, it means leveraging established brands and an installed base in feeding-related products. The company’s recent acquisitions suggest another element of the recipe: add products that can be sold to overlapping physicians and provider systems rather than enter entirely unrelated markets. Avanos does not seem to be pursuing low-cost leadership. Instead, it is trying to win on product familiarity, clinician training, protocol adoption, and a higher-value mix of procedure-driven consumables and branded devices.

4. 1d. What capabilities must Avanos have in place?

   To make that strategy work, Avanos needs several capabilities that are specific to medtech execution. These include strong quality and regulatory systems; applied engineering and clinical development; specialized manufacturing and sterilization oversight; physician and clinician education; reimbursement and health-economics support in pain categories; and disciplined integration of acquired technologies. It also needs a sales model that can cover different call points effectively, from hospital value-analysis committees and supply-chain buyers to anesthesiologists, pain specialists, orthopedic surgeons, and neonatal clinicians. Distributor management is another important capability outside the United States.

5. 1e. What management systems does Avanos require?

   Avanos needs management systems that reinforce precision rather than sprawl. In practice, that means rigorous quality-system compliance, post-market surveillance, product lifecycle management, demand planning for sterile medical devices, and tight capital-allocation discipline. Because the company has used M&A to reshape the portfolio, integration governance matters. Because its margins depend heavily on mix and execution, management also needs strong gross-margin, pricing, and procurement dashboards. Finally, a specialist sales force requires clear territory design, training systems, reimbursement support processes, and metrics that track not just unit sales but account penetration, procedure adoption, and consumable pull-through.

2. What Are the Current Strategic Initiatives of Avanos?

Avanos’s recent public actions point to a set of concrete strategic initiatives rather than a generic “grow the core” message. The most visible initiatives are concentrated in pain adjacencies, portfolio integration, digestive-health defense, and operating improvement.

• Expanding the interventional and chronic-pain platform. Avanos has been building beyond its legacy surgical pain offerings into higher-growth pain categories. Publicly disclosed transactions and portfolio moves indicate a push into radiofrequency-based chronic pain treatment and adjacent musculoskeletal pain offerings. This matters strategically because these categories can carry better growth and margin characteristics than mature hospital consumables.
• Using acquisitions to broaden the orthopedic and pain call point. The addition of businesses such as Diros Technology and OrthogenRx suggests a deliberate attempt to create a broader set of products sold to overlapping physicians and sites of care. That can improve sales-force productivity if a single rep or specialist team can discuss multiple pain and recovery products with the same account base.
• Scaling the recovery franchise. Game Ready extends Avanos into post-operative recovery and sports-medicine rehabilitation. The strategic logic is not only product diversification; it also creates another branded solution in the musculoskeletal pathway, adjacent to pain treatment and procedure recovery.
• Defending and refreshing Digestive Health. Digestive health remains a foundational business because it is repeat-driven and supported by established brands. Avanos has continued to emphasize enteral feeding, neonatal and pediatric feeding, and related access products. The underlying initiative is to maintain share and reliability in a category where clinician familiarity and installed base matter.
• Improving portfolio mix and profitability. Management communications have consistently emphasized profitable growth, not just revenue growth. For Avanos, that likely means shifting mix toward higher-value pain products, integrating acquired businesses efficiently, and driving productivity across manufacturing, procurement, and SG&A.
• Maintaining disciplined capital allocation. Avanos’s deal pattern does not look like indiscriminate roll-up behavior. It looks more targeted: add technologies that strengthen existing channels and care pathways, while preserving balance-sheet flexibility and operating cash generation.

3. What Is the Business Model of Avanos?

Avanos is primarily a product-sales medtech company, not a subscription business. Customers buy medical devices, procedure kits, disposable components, and selected capital equipment used in pain management, recovery, and digestive health. The economics are attractive when a capital product or installed base leads to recurring use of related disposables or repeat procedures.

• What customers actually buy: hospitals, surgery centers, pain clinics, orthopedic practices, and alternate-site providers buy feeding tubes, enteral accessories, pain catheters, infusion-related items, radiofrequency procedure products, recovery systems, and related consumables.
• Recurring versus one-time revenue: a meaningful share of Avanos’s model appears repeat-driven. Digestive-health products are often replaced or reordered regularly. In pain, procedure-linked consumables and accessories can recur as physicians adopt a therapy. Capital items such as generators, pumps, or recovery units are more episodic, but they can anchor future consumable demand and account loyalty.
• Revenue model: the company mainly sells physical products. It is not a software or subscription model. Service, training, and clinical support matter commercially, but the revenue engine is device and consumable sales.
• How pricing power works: Avanos’s pricing power appears moderate and category-specific. It is strongest where products are clinically differentiated, embedded in protocols, protected by brand familiarity, or linked to physician preference. It is weaker where hospital procurement treats products as closer substitutes.
• Why the business mix matters: mix is central to Avanos economics. Higher-growth pain products and procedure consumables should generally support better gross margins than more mature feeding or hospital products. That is one reason recent acquisitions matter strategically.
• What drives gross margin, operating margin, and cash generation: gross margin depends on product mix, pricing discipline, manufacturing efficiency, sterilization and freight costs, and the ratio of branded specialty products to more standardized items. Operating margin depends on how efficiently Avanos supports a specialized sales force and integrates acquired businesses. Cash generation is influenced by inventory, receivables, disciplined capital spending, and the fact that the business is not as asset-heavy as sectors such as pharma manufacturing or aerospace.

4. What Products and/or Services Does Avanos Sell?

Avanos sells medical devices and related consumables across two main product franchises: Pain Management and Recovery, and Digestive Health. The portfolio is narrower than that of a diversified medtech company, but it is built around categories where brand familiarity and clinician workflow matter.

Pain Management and Recovery

• ON-Q: surgical pain-management systems designed to deliver local anesthetic and support opioid-sparing recovery pathways.
• COOLIEF and related interventional-pain products: radiofrequency-based products used in chronic pain procedures, including musculoskeletal pain applications.
• Game Ready: cold and compression therapy used in orthopedic and post-operative recovery.
• Diros-related technologies: radiofrequency generators and associated procedural tools that deepen Avanos’s pain portfolio.
• OrthogenRx products: hyaluronic acid knee osteoarthritis injections such as GenVisc 850 and TriVisc, which extend the company into adjacent musculoskeletal pain management.

Digestive Health

• MIC-KEY: low-profile enteral feeding tubes and related devices, a long-established brand in enteral feeding.
• CORTRAK: enteral access placement technology used to support feeding tube placement.
• NeoMed: neonatal and pediatric enteral feeding products, adding strength in highly specialized care settings.
• Related enteral accessories: extension sets, valves, drainage products, and other consumables associated with enteral feeding and care.

From an economic perspective, Digestive Health appears to be an important recurring base business, while the interventional and musculoskeletal pain portfolio has become strategically important because it offers faster growth and potentially better mix. ON-Q remains a meaningful branded franchise, but the newer growth narrative is more closely tied to chronic pain, recovery, and orthopedic-adjacent products.

5. What Are the Key Competitors or Peers of Avanos?

No single competitor mirrors Avanos across its full portfolio, because the company operates across several specialized categories. Its competitive set changes by product line.

• Cardinal Health: a relevant competitor in enteral feeding, particularly through the Kangaroo franchise and its strong acute-care channel presence.
• Teleflex: a broad hospital-device company with GI, access, and critical-care products that overlap with some digestive-health call points.
• Vygon: a specialist in neonatal, enteral, and access devices, especially relevant in pediatric and international markets.
• B. Braun: competes in infusion and pain-delivery products and is relevant in hospital-based pain-management channels.
• Enovis (including DJO): one of the closest peers for recovery and rehabilitation products, especially around cold-compression therapy and orthopedic recovery.
• Boston Scientific: a larger interventional-pain and chronic-pain peer; not a perfect product match, but competes for physician attention and pain-treatment budgets.
• Abbott: another important chronic-pain peer through neuromodulation and pain-management therapies, more a substitute in pain pathways than a direct line-for-line competitor.
• Medtronic: a broad medtech company with pain-therapy offerings and strong hospital relationships; again, more a pain-pathway competitor than a direct replica of Avanos.
• Stryker: relevant through orthopedic and sports-medicine relationships, where Avanos is building recovery and musculoskeletal pain exposure.
• Cook Medical: a useful digestive-health and access peer in certain hospital-based feeding and catheter-related categories.

The competitive implication is important: Avanos is usually not facing one all-encompassing rival. It is often competing franchise by franchise, where product reputation, clinical support, and account penetration can matter more than total corporate size.

6. What Is the Marketing Strategy of Avanos?

Avanos’s marketing strategy is largely clinical, educational, and account-based rather than consumer-oriented. This is typical for medtech, but in Avanos’s case it is especially true because many of its products require clinician confidence, training, and protocol adoption.

• Clinical evidence and education: in pain management, the company needs physicians to believe the therapy works, fits workflow, and can be reimbursed. That makes medical education, conference presence, and clinician training central marketing tools.
• Brand marketing within professional channels: brands such as ON-Q, COOLIEF, MIC-KEY, and Game Ready matter because clinicians remember brands that have proven reliable in practice. This is not mass-market branding; it is reputation-building inside hospitals, surgery centers, and specialty clinics.
• Account-based marketing: hospitals and integrated delivery networks often require value-analysis approval, protocol support, and economic justification. Avanos therefore benefits from marketing that combines clinical outcomes, workflow arguments, and purchasing value.
• Channel and field marketing: international growth depends heavily on distributors, so training, materials, and local market-development support are important. Field marketing also matters in orthopedic and pain categories where procedure adoption can be highly local.
• Reimbursement-sensitive messaging: in interventional pain and musculoskeletal categories, marketing must often support coding, coverage, and health-economic understanding, not just product features.

Marketing appears to be a supporting capability rather than the sole differentiator. The stronger differentiators are clinical fit, sales execution, installed base, and specialist training. But without effective education and account development, those strengths would be harder to monetize.

7. What Are the Key Customer Segments of Avanos?

Avanos serves several distinct healthcare customer groups, and the mix matters because buying criteria differ sharply by setting.

• Acute-care hospitals: still a core customer base for digestive-health products, surgical pain products, and selected recovery offerings. Hospitals matter because they influence protocol adoption, value-analysis approval, and broader system standardization.
• Ambulatory surgery centers: an increasingly important site of care for pain and recovery products as procedures shift out of hospitals.
• Interventional pain specialists and pain clinics: strategically important for COOLIEF and other chronic-pain technologies.
• Orthopedic and sports-medicine providers: important for Game Ready and musculoskeletal pain products, and increasingly relevant as Avanos expands adjacent offerings.
• Neonatal and pediatric care settings: a specialized but valuable customer segment for NeoMed and related digestive-health products.
• Home health, alternate-site care, and durable medical equipment channels: relevant for enteral feeding products that continue beyond the hospital stay.
• Distributors and channel partners: especially important outside the United States, where they help extend reach without a fully built-out direct commercial infrastructure.

Overall, Avanos is diversified across care settings, but its economic center of gravity remains provider-facing rather than consumer-facing. The customer mix also explains why selling skill and clinical training are so important: the company serves both centralized procurement organizations and highly specialized clinicians.

8. What Is the Sales Model of Avanos?

Avanos uses a specialist medtech sales model. In the United States, it appears to rely primarily on direct sales teams supported by clinical education and account-development capabilities. Internationally, distributors and channel partners appear to play a larger role.

• Direct specialty selling: pain-management and recovery products often require a rep who understands physician workflows, procedure economics, and training needs.
• Hospital and IDN selling: digestive-health and surgical products also require engagement with supply-chain leaders, value-analysis committees, and group purchasing organization frameworks.
• Capital-plus-consumables logic: some categories use capital equipment or installed systems to create future product demand. That makes sales execution more strategic than simply winning a one-time order.
• Distributor leverage internationally: Avanos can expand into more markets without replicating a full direct sales structure everywhere, but this makes distributor selection, training, and incentive alignment critical.

The channel structure affects growth and pricing in several ways. Direct coverage improves customer intimacy and procedure adoption in the United States, especially in pain and orthopedics. Distributor-led markets may be less costly to enter, but they typically provide less direct control over messaging and account development. For consultants, this kind of model often creates high-value work around territory design, sales-force effectiveness, distributor strategy, and account-pricing architecture.

9. In What Geographies Does Avanos Operate?

Avanos is a U.S.-centered company with international reach. The United States is its largest market and the primary driver of commercial focus, especially in pain management, recovery, and hospital-based digestive-health sales. Internationally, the company sells into Europe, Canada, Latin America, the Middle East, and parts of Asia-Pacific through a mix of direct activities and distributors.

Operationally, the physical footprint appears more concentrated than the sales footprint. Public disclosures indicate a North American operating base centered on corporate leadership in Alpharetta, Georgia, with manufacturing and supply-chain activities in North America, including Mexico. That is a common structure for a mid-sized medtech company: the commercial footprint reaches many countries, but the manufacturing and management footprint is comparatively compact.

This geographic profile has strategic implications. It gives Avanos strong exposure to the U.S. reimbursement and procedure environment, which is helpful for its pain businesses, but it also means international growth often depends on distributor quality, local regulatory registrations, and the ability to translate clinical value into country-specific care pathways.

10. Who Are the Owners of Avanos?

Avanos is a publicly traded company listed under the ticker AVNS. Ownership appears broadly dispersed, and the company does not appear to have a controlling shareholder. As is typical for U.S. public medtech companies, the shareholder base in recent public filings has been led primarily by institutional investors, with firms such as Vanguard, BlackRock, and State Street commonly appearing among significant holders. Insider ownership exists but does not appear to amount to control. Because ownership data changes over time, investors should verify the latest proxy statement and recent 13F filings for current positions.

11. How Is Avanos Organized?

Legally, Avanos Medical, Inc. is the public parent company. For external reporting, the business has been presented as one reportable segment rather than a collection of separately reported divisions. Practically, however, the company is organized around product franchises, most notably Pain Management and Recovery and Digestive Health.

That practical organization matters more than the legal chart for understanding how the business runs. Commercial teams are likely aligned by specialty and geography, while central functions such as quality, regulatory, supply chain, R&D, finance, and human resources support the portfolio. Recent acquisitions also imply a need for integration mechanisms that preserve the strengths of acquired technologies while bringing them into a common operating model.

In other words, Avanos is best understood as a focused medtech platform with shared infrastructure, not as a holding company managing unrelated businesses.

12. How Does Avanos Operate?

On a day-to-day basis, Avanos operates like a specialized medtech manufacturer and commercializer. The company’s value creation comes from developing or acquiring clinically relevant devices, manufacturing and sourcing them reliably, securing regulatory compliance, and driving repeat use through training and account penetration.

1. Product development and clinical/regulatory work: Avanos designs products internally and supplements that capability with acquisitions. In medtech, engineering alone is not enough; products must be supported by quality documentation, regulatory clearances, and post-market monitoring.
2. Sourcing and manufacturing: the company procures medical-grade components, assembles devices and consumables, manages sterilization and packaging, and must maintain validated processes. Reliability is critical because hospitals and clinicians do not tolerate supply inconsistency in patient-facing devices.
3. Commercial execution: sales representatives and clinical specialists work with hospitals, surgery centers, and specialists to win approvals, support training, and drive utilization.
4. Installed-base support and consumable pull-through: where Avanos places equipment or secures procedural adoption, future orders for accessories, disposables, or related products can follow.
5. Post-market quality and service: complaints handling, field support, safety monitoring, and product lifecycle management are continuous operating requirements.

The biggest operational complexities are typical for medtech but especially important for Avanos: quality-system execution, supply reliability for sterile products, reimbursement sensitivity in pain procedures, and the challenge of integrating acquired product lines without disrupting the customer experience.

13. What Are the Growth Opportunities for Avanos?

Management-stated priorities and recent portfolio actions suggest several credible growth opportunities for Avanos.

• Scale interventional and chronic pain. This is the clearest strategic opportunity. Chronic pain, radiofrequency procedures, and musculoskeletal pain management offer a path to faster growth and better mix than more mature legacy categories.
• Build a broader musculoskeletal pathway. Combining products such as COOLIEF, Game Ready, and OrthogenRx creates the possibility of serving overlapping orthopedic and pain call points with a broader set of solutions.
• Expand Digestive Health in specialized segments. Neonatal and pediatric feeding, home enteral care, and selected international markets can support steady growth in a business that is already repeat-driven.
• Increase international penetration. Because Avanos remains U.S.-centric, there is room to improve distributor coverage, local market development, and product registration in selected international markets.
• Use tuck-in M&A. Recent history suggests Avanos sees acquisitions as a practical way to add technology, brands, and call-point density without attempting to build every adjacent platform organically.
• Improve mix, pricing, and productivity. Growth does not need to come only from units. Margin expansion can also come from shifting the portfolio toward higher-value products, improving pricing discipline, and driving procurement and manufacturing efficiency.

The main constraints are also clear: reimbursement risk in pain categories, competition from larger medtech firms, hospital budget pressure, regulatory and quality requirements, and the execution burden of integrating acquisitions while maintaining service levels in the core digestive-health business.

14. What Is the History of Avanos?

Avanos in its current form begins with the 2014 spin-off of Kimberly-Clark’s health care business as Halyard Health. That origin matters because it explains the company’s legacy exposure to hospital products and enteral care.

A major turning point came in 2018, when Halyard changed its name to Avanos Medical after selling the Surgical & Infection Prevention business to Owens & Minor. That move sharpened the company’s identity and narrowed its focus toward medical devices rather than broad disposable healthcare supplies.

Since then, Avanos has increasingly looked like a portfolio-shaping story. It strengthened digestive health with NeoMed, expanded into post-operative recovery with Game Ready, added radiofrequency pain technology through Diros Technology, and broadened musculoskeletal pain exposure through OrthogenRx. The through-line across these moves is strategic specialization: Avanos has been moving away from being a legacy spin-off with mixed product exposure and toward being a more focused medtech company centered on pain, recovery, and digestive health.

15. What Are the Key Suppliers to Avanos?

Suppliers matter to Avanos because many of its products are regulated, sterile, and clinically sensitive. The company does not publicly emphasize a long list of named suppliers, but the important supplier categories are relatively clear.

• Medical-grade plastics, tubing, and molded components: critical for feeding tubes, catheter-based products, and disposable accessories.
• Needles, cannulae, metals, and specialty components: important in interventional pain and related procedure products.
• Electronics and equipment components: relevant for generators, pumps, and recovery systems.
• Sterilization providers and sterile-packaging vendors: strategically important because sterilization capacity, validation, and regulatory compliance can become bottlenecks.
• Contract manufacturing and logistics partners: useful where the company supplements internal manufacturing or needs flexible capacity.

Supplier structure matters strategically because medtech components often cannot be swapped quickly. Qualification cycles are long, regulatory files may need updating, and some parts may be effectively sole sourced for a period of time. That makes dual sourcing, quality audits, and supplier-risk management especially important.

16. What Are the Key Brands Owned by Avanos?

Brands are an important strategic asset for Avanos because many of its products are chosen in clinical environments where reliability, familiarity, and training matter. The company’s key brands are not consumer brands in the classic sense; they are professional brands with meaning inside hospitals and specialty practices.

17. How Does the Supply Chain of Avanos Function?

Avanos’s supply chain is important because it supports sterile, regulated products sold into healthcare environments that require high service levels. The supply chain is not just a cost function; it is a reliability function tied directly to customer trust and gross margin.

1. Sourcing: Avanos procures medical-grade raw materials, molded parts, electronics, metals, packaging, and other specialized inputs.
2. Manufacturing and assembly: products are manufactured or assembled through a mix of internal operations and outside partners, depending on the category.
3. Sterilization and quality release: many products require validated sterilization processes, documentation, and lot release controls before shipment.
4. Inventory and distribution: the company must balance service levels against working capital, especially for products with clinical urgency or recurring hospital demand.
5. Delivery to multiple care settings: products move to hospitals, ambulatory centers, specialty clinics, distributors, and alternate-site or home-care channels.
6. Training and post-sale support: for certain products, supply chain execution is intertwined with field support because proper use influences reorder rates and account retention.

Supply-chain reliability is strategically important for Avanos for three reasons. First, many devices cannot tolerate stock-outs without risking account loss. Second, sterilization and regulatory validation can limit flexibility. Third, as the portfolio expands through acquisitions, harmonizing planning, procurement, and fulfillment becomes a meaningful management challenge.

18. What Is the R&D Strategy of Avanos?

R&D is an important part of Avanos’s strategy, but it appears to be applied and commercially targeted rather than basic-science oriented. This is typical for a device company of Avanos’s size. The goal is not open-ended research; it is to improve procedures, enhance usability, support regulatory claims, and add clinically relevant adjacencies.

In pain management, the R&D agenda likely centers on devices, disposables, and procedural systems that can improve clinician workflow, expand treatment use cases, and support better outcomes in surgical, interventional, or musculoskeletal settings. In digestive health, product development is more likely to focus on tube design, accessories, placement systems, neonatal and pediatric needs, and other practical improvements that matter to caregivers.

Avanos also appears to use M&A as a complement to internal R&D. That is strategically rational for a mid-sized medtech company: instead of building every adjacent technology from scratch, it can acquire clinically proven platforms and then use its commercial and operating infrastructure to scale them. The key managerial challenge is balancing line-extension innovation with selective larger bets that can move the growth profile of the portfolio.

19. What Major Acquisitions Has Avanos Made?

Acquisitions have played an important role in Avanos’s evolution from a legacy spin-off into a more focused pain and digestive-health company. The pattern is notable because the deals appear adjacency-driven rather than purely financial.

The broader point is that M&A has been a portfolio-shaping tool for Avanos. The company does not appear to be pursuing scale for its own sake. Instead, it is using acquisitions to add technologies, brands, and call-point density in categories adjacent to existing commercial capabilities.

20. How Companies Like Avanos Leverage Independent Consultants through Umbrex

Umbrex has grown a global community of over 8,000 independent management consultants based in more than 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top consulting firms. Companies like Avanos use Umbrex when they need the analytical rigor and practical execution support associated with top-tier firms, but do not need a full consulting team and its overhead. Umbrex consultants work across strategy, operations, organization, marketing, sales, finance, technology, ERP, and AI. For a company like Avanos, the most relevant projects are usually tied to portfolio focus, channel effectiveness, margin improvement, post-acquisition integration, and growth in specialty care pathways.

• Interventional pain growth strategy: size specific procedure segments, prioritize target specialties, and identify the highest-return growth pockets for COOLIEF and related pain technologies.
• Musculoskeletal portfolio integration: design the commercial model for selling Game Ready, OrthogenRx, and pain products through overlapping orthopedic and sports-medicine call points.
• U.S. sales-force effectiveness: redesign territories, roles, quotas, and incentive plans for specialty reps covering hospitals, ambulatory surgery centers, and physician offices.
• International distributor strategy: assess market-by-market opportunities, rationalize distributor networks, and build better training and channel-governance processes.
• Pricing and contracting: strengthen value messaging, GPO strategy, hospital contracting, and price-discipline tools by product and account type.
• Supply-chain resilience program: evaluate sole-source risk, sterilization bottlenecks, procurement concentration, and inventory policies for critical pain and digestive-health products.
• Manufacturing and gross-margin improvement: identify productivity opportunities in sourcing, footprint, SKU rationalization, and operations planning.
• Post-acquisition integration: support integration planning for tuck-in acquisitions, including commercial overlap, back-office harmonization, and synergy tracking.
• R&D and portfolio prioritization: build stage-gate processes and investment frameworks that balance internal development with future tuck-in acquisitions.
• ERP, data, and AI-enabled planning: improve demand forecasting, service-level visibility, quality analytics, and management dashboards across a more complex multi-franchise portfolio.